Additional world-leading expertise stands to further accelerate the Company’s pipeline programs targeting rare neurodegenerative diseases OXFORD, United Kingdom, July 16, 2025 (GLOBE NEWSWIRE) -- Evox ...

Tivity Health President and Chief Operating Officer, Caroline Khalil, will work alongside Ms. Deckmann leveraging her deep leadership experience in Medicare and commercial fitness and operational ...

This information is synthesized by PanOmiQ™ of BioAro Inc, World’s Fastest AI powered MultiOmics Platform, integrated with wearable data (HRV, sleep, workload), and delivered through easy-to-use ...

“We are witnessing a historic shift in rehabilitation technology—from basic functional support to the pursuit of quality living,” Dr. Wang Erqi, Jin Medical’s CEO and Chairman of the Board, remarked. ...

In a defining moment for healthcare, the Barrett Family Foundation has made a transformative donation to St. Joseph’s Health Centre—part of Unity Health Toronto—to create the Barrett Centre for ...

Tuspetinib in combination with venetoclax and azacitidine (the TUS+VEN+AZA triplet) continues to demonstrate exciting antileukemic activity and safety across genetically diverse populations of newly ...

The Ratio Change is aimed to bring the price of the Company’s ADRs into compliance with the Nasdaq $1.00 minimum bid price per share requirement, although Biodexa can give no assurance that the Ratio ...

In addition to DuraPro™, Globus Medical launched Verzera™, a navigated high-speed drill system integrated with the ExcelsiusGPS and ExcelsiusHub system. Verzera™ augments existing workflows for ...

Event: Biotricity Fiscal 2025 Fourth Quarter Financial Results and Business Update Call Date: Friday, July 18, 2025 Time: 4:45 PM ET (1:45 PM PT) Toll Free: 1-877-269-7751 International: ...

Combined Company to Trade on Nasdaq Under Ticker “IMA” Ikena Announces 1-for-12 Reverse Stock Split of Ikena Common Stock . BOSTON and SAN DIEGO, July 15, 2025 (GLOBE NEWSWIRE ...

Gain intends to use the net proceeds from the offering to continue clinical and nonclinical development of its lead product candidate GT-02287 for the treatment of neurodegenerative diseases, ...

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, ...